Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced it has received a letter from the U.S. Food and Drug Administration dated September 2, 2020 closing out the Warning Letter it received from the FDA on October 18, 2018 concerning ReSure® Sealant.
September 8, 2020
· 7 min read